Results 111 to 120 of about 60,975 (303)
Drug-induced hemolytic anemia: Pharmacological aspects
Drug-induced hemolytic anemia is a very rare but potentially lethal adverse drug reaction, which can take the form of oxidative damage to vulnerable erythrocytes (as in glucose-6-phosphate dehydrogenase deficiency), drug-induced thrombotic ...
Rosselet, A. +3 more
core +1 more source
ABSTRACT Hemolytic disease of the fetus and newborn (HDFN) remains a significant concern in prenatal care primarily caused by maternal alloimmunization against fetal red blood cell antigens, most commonly the D antigen. Noninvasive fetal RHD genotyping, used as a screening tool, enables targeted antenatal prophylaxis and has been implemented in several
Emilie Thorup +4 more
wiley +1 more source
ABSTRACT Sickle cell disease (SCD) affects millions worldwide but has limited treatment options, most of which carry significant side effects. At present, the only curative treatment for SCD is allogeneic or gene‐modified autologous hematopoietic stem cell (HSC) transplantation (Tx).
Oluwaseun O. Babatunde +4 more
wiley +1 more source
Hemolytic anemia presenting with idiopathic intracranial hypertension
We report on an 8-year-old girl with hemolytic anemia because of infection with parvovirus B19 and increased intracranial pressure. She presented acutely with headache, vomiting, and mild scleral and mucosal icterus.
Thanasiou-Metaxa, Miranda +4 more
core +1 more source
GLUT1 Deficiency Syndrome with Coexistent Movement Disorder and Anemia
Movement Disorders Clinical Practice, EarlyView.
Sangeetha Yoganathan +12 more
wiley +1 more source
ABSTRACT Objective To describe the prenatal diagnosis, evolution, and perinatal management of kaposiform hemangioendothelioma (KHE) complicated by the Kasabach–Merritt phenomenon (KMP), and to report the first documented use of maternal sirolimus therapy (MST) in this setting. Methods We retrospectively reviewed four fetuses with a prenatal soft‐tissue
Antoine Fraissenon +11 more
wiley +1 more source
Bortezomib: friend or foe of hemolytic anemia?
Over the last decade, bortezomib moved in a stepwise fashion from a benchside promise into a bedside reality and is currently an important tool in the treatment of plasma cell disorders.
Constantin A Dasanu
core +1 more source
Sickle Cell Disease: Historical Overview and Current Therapies
ABSTRACT Sickle cell disease (SCD) affects millions worldwide, yet the limited treatment options currently available do not always adequately control the disease and carry significant side effects. At present, the only curative treatment is hematopoietic stem cell (HSC) transplantation, a procedure that carries considerable challenges and numerous ...
Oluwaseun O. Babatunde +4 more
wiley +1 more source
Thymoma with Autoimmune Hemolytic Anemia
A 38-year-old Japanese male was referred to our hospital with abnormal chest X-ray results and severe Coombs-positive hemolytic anemia. He was diagnosed with a stage IV, WHO type A thymoma and was treated with oral prednisolone (1 mg/kg/day) and ...
Ryuji Hayashi +4 more
core +1 more source
Kaposiform hemangioendothelioma: Diagnosis and treatment
Vascular endothelial growth factor‐C (VEGF‐C)/vascular endothelial growth factor receptor‐3 (VEGFR‐3) and angiopoietin‐2 (Ang‐2)/tyrosine kinase with immunoglobulin‐like and EGF‐like domain 2 (TIE2) signaling pathways play an important role in lymphangiogenesis.
Yi Tian +5 more
wiley +1 more source

